Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes

被引:12
作者
Zhang, Chen-Hao [1 ,2 ]
Li, Ming [3 ]
Lin, You-Pei [1 ,2 ]
Gao, Qiang [1 ,2 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat, Shanghai, Peoples R China
[2] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; clinical trials; targeted therapy; immunotherapy; liver cancer; hepatitis B virus; hepatitis C virus; POSITIVE SOLID TUMORS; PHASE-III; DOUBLE-BLIND; RETROSPECTIVE ANALYSIS; SORAFENIB TREATMENT; PATIENTS PTS; OPEN-LABEL; MULTICENTER; TRIAL; CABOZANTINIB;
D O I
10.2174/1566523220666200628014530
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage that can only benefit from systemic treatments. Although HCC is highly treatmentresistant, significant achievements have been made in the molecular targeted therapy and immunotherapy of HCC. In addition to regorafenib, cabozantinib and ramucirumab were approved for the second- line targeted treatment by the FDA after disease progression on sorafenib. Nivolumab failed to demonstrate remarkable benefit in overall survival (OS) as first-line therapy, while pembrolizumab did not achieve pre-specified statistical significance in both OS and progression-free survival (PFS) as second-line treatment. Combinations of targeted agents, immune checkpoint inhibitors and other interventions showed favorable results. In this review, we summarized the progress of systemic therapy in HCC and discussed the future directions of the treatment of HCC.
引用
收藏
页码:84 / 99
页数:16
相关论文
共 110 条
[1]   Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].
Abou-Alfa, G. K. ;
Meyer, T. ;
Cheng, A. -L. ;
El-Khoueiry, A. B. ;
Rimassa, L. ;
Ryoo, B. -Y. ;
Cicin, I. ;
Merle, P. ;
Chen, Y. H. ;
Park, J. -W. ;
Blanc, J. -F. ;
Bolondi, L. ;
Klumpen, H. -J. ;
Chan, S. L. ;
Zagonel, V. ;
Pressiani, T. ;
Ryu, M. -H. ;
Venook, A. P. ;
Hessel, C. ;
Borgman-Hagey, A. E. ;
Schwab, G. ;
Kelley, R. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63
[2]   Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial [J].
Abou-Alfa, Ghassan K. ;
Shi, Qian ;
Knox, Jennifer J. ;
Kaubisch, Andreas ;
Niedzwiecki, Donna ;
Posey, James ;
Tan, Benjamin R., Jr. ;
Kavan, Petr ;
Goel, Rakesh ;
Lammers, Philip E. ;
Bekaii-Saab, Tanios S. ;
Tam, Vincent C. ;
Rajdev, Lakshmi ;
Kelley, Robin K. ;
El Dika, Imane ;
Zemla, Tyler ;
Potaracke, Ryan, I ;
Balletti, Jennifer ;
El-Khoueiry, Anthony B. ;
Harding, James H. ;
Suga, Jennifer M. ;
Schwartz, Lawrence H. ;
Goldberg, Richard M. ;
Bertagnolli, Monica M. ;
Meyerhardt, Jeffrey ;
O'Reilly, Eileen M. ;
Venook, Alan P. .
JAMA ONCOLOGY, 2019, 5 (11) :1582-1588
[3]   Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma [J].
Abou-Alfa, Ghassan K. ;
Puig, Oscar ;
Daniele, Bruno ;
Kudo, Masatoshi ;
Merle, Philippe ;
Park, Joong-Won ;
Ross, Paul ;
Peron, Jean-Marie ;
Ebert, Oliver ;
Chan, Stephen ;
Poon, Tung Ping ;
Colombo, Massimo ;
Okusaka, Takuji ;
Ryoo, Baek-Yeol ;
Minguez, Beatriz ;
Tanaka, Takayoshi ;
Ohtomo, Toshihiko ;
Ukrainskyj, Stacey ;
Boisserie, Frederic ;
Rutman, Olga ;
Chen, Ya-Chi ;
Xu, Chao ;
Shochat, Eliezer ;
Jukofsky, Lori ;
Reis, Bernhard ;
Chen, Gong ;
Di Laurenzio, Laura ;
Lee, Ray ;
Yen, Chia-Jui .
JOURNAL OF HEPATOLOGY, 2016, 65 (02) :289-295
[4]   Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma [J].
Ally, Adrian ;
Balasundaram, Miruna ;
Carlsen, Rebecca ;
Chuah, Eric ;
Clarke, Amanda ;
Dhalla, Noreen ;
Holt, Robert A. ;
Jones, Steven J. M. ;
Lee, Darlene ;
Ma, Yussanne ;
Marra, Marco A. ;
Mayo, Michael ;
Moore, Richard A. ;
Mungall, Andrew J. ;
Schein, Jacqueline E. ;
Sipahimalani, Payal ;
Tam, Angela ;
Thiessen, Nina ;
Cheung, Dorothy ;
Wong, Tina ;
Brooks, Denise ;
Robertson, A. Gordon ;
Bowlby, Reanne ;
Mungall, Karen ;
Sadeghi, Sara ;
Xi, Liu ;
Covington, Kyle ;
Shinbrot, Eve ;
Wheeler, David A. ;
Gibbs, Richard A. ;
Donehower, Lawrence A. ;
Wang, Linghua ;
Bowen, Jay ;
Gastier-Foster, Julie M. ;
Gerken, Mark ;
Helsel, Carmen ;
Leraas, Kristen M. ;
Lichtenberg, Tara M. ;
Ramirez, Nilsa C. ;
Wise, Lisa ;
Zmuda, Erik ;
Gabriel, Stacey B. ;
Meyerson, Matthew ;
Cibulskis, Carrie ;
Murray, Bradley A. ;
Shih, Juliann ;
Beroukhim, Rameen ;
Cherniack, Andrew D. ;
Schumacher, Steven E. ;
Saksena, Gordon .
CELL, 2017, 169 (07) :1327-+
[5]  
[Anonymous], 2019, NCCN Clinical Practice Guidelines in Oncology: Prostate cancer
[6]  
[Anonymous], 2019, J CLIN ONCOL, DOI DOI 10.1200/JC0.2019.37.4_SUPP1.336
[7]  
[Anonymous], 2019, J CLIN ONCOL, DOI DOI 10.1200/JC0.2019.37.4_SUPP1.365
[8]  
[Anonymous], 2019, J CLIN ONCOL, DOI DOI 10.1200/JC0.2019.37.15_SUPP1.4072
[9]  
[Anonymous], 2019, J CLIN ONCOL, DOI DOI 10.1200/JC0.2019.37.4_SUPP1.268
[10]  
[Anonymous], 2019, FRONT ONCOL, DOI DOI 10.3389/F0NC.2019.00019